Bush Medicare plan pays little heed to industry concerns
This article was originally published in Clinica
President Bush last week unveiled a framework he intends to use in negotiating with Congress on how to modernise the Medicare programme and put it on a more secure financial footing. But in defining his eight principles for reform, he paid little more than lip service to concerns raised by the medical device industry.
You may also be interested in...
House and Senate Democrats sponsor legislation to authorize FTC enforcement against sales of "consumer goods and services at an unconscionably excessive price during the" COVID-19 pandemic. "It’s outrageous that some companies and individuals are taking advantage of consumers by price-gouging," says Energy and Commerce Committee Chairman Frank Pallone.
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.
A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”